Relationship between Advanced Glycation End Products and Plaque Progression in Patients with Acute Coronary Syndrome: The JAPAN-ACS Sub-study

Table 1 Baseline AGEs and sRAGE levels

Background		N = 208	AGEs^* (U/mL)	P-value	sRAGE^* (pg/mL)	P-value
Statin	Atorvastatin	98	8.56 ± 2.35	0.99	736 (494–1099)	0.6
Statin	Pitavastatin	110	8.56 ± 2.04	0.99	681 (492–1016)	0.6
Gender	Women	42	8.00 ± 2.22	0.06	704 (413–1104)	0.8
Gender	Men	166	8.71 ± 2.17	0.06	692 (494–1004)	0.8
Diabetes mellitus	No	146	8.44 ± 2.14	0.2	692 (481–1015)	0.2
	Yes	62	8.86 ± 2.28		755 (552–1096)
Hypertension	No	81	8.46 ± 2.22	0.6	684 (489–1022)	0.8
	Yes	127	8.63 ± 2.18		718 (494–1095)
Smoking	No	112	8.25 ± 2.14	0.028	692 (541–1050)	0.5
Smoking	Yes	96	8.92 ± 2.20	0.028	707 (453–1037)	0.5
ST elevation	No	74	8.63 ± 2.10	0.7	720 (537–949)	0.8
ST elevation	Yes	134	8.53 ± 2.24	0.7	683 (472–1080)	0.8

*Data of AGEs were expressed as mean ± SD and those of sRAGE were median (interquartile range). AGEs, Advanced glycation end products; sRAGE, serum Receptor of AGE.

ISSN: 1475-2840